Video Interview with Ali Pashazadeh, Treehill Partners CEO
A series of short-form clips from a recent video interview with Ali Pashazadeh, CEO and Founder of Treehill Partners, has been published on LinkedIn, examining the forces behind the extraordinary growth of the GLP-1 drug class.
Drawing on both his clinical and advisory background, Pashazadeh looks past the headline sales figures – with the class now among the highest-selling in the world – to the questions that will determine the long-term winners: the durability of the effect, the tolerability profile, and the mechanisms likely to follow the current generation. His central point is that the size of the market is not the same as the durability of the science underpinning it.
Watch the clips here: https://www.linkedin.com/feed/update/urn:li:activity:7467892856523902976/